176 related articles for article (PubMed ID: 37103889)
21. Alternative Complement Pathway Is Activated and Associated with Galactose-Deficient IgA
Chiu YL; Lin WC; Shu KH; Fang YW; Chang FC; Chou YH; Wu CF; Chiang WC; Lin SL; Chen YM; Wu MS
Front Immunol; 2021; 12():638309. PubMed ID: 34177889
[TBL] [Abstract][Full Text] [Related]
22. Measurement of galactosyl-deficient IgA1 by the monoclonal antibody KM55 contributes to predicting patients with IgA nephropathy with high risk of long-term progression.
Martín-Penagos L; Fernández-Fresnedo G; Benito-Hernández A; Mazón J; de Cos M; Oviedo MV; San Segundo D; López-Hoyos M; Gómez-Román J; Ruiz JC; Rodrigo E
Nefrologia (Engl Ed); 2021; 41(3):311-320. PubMed ID: 33741175
[TBL] [Abstract][Full Text] [Related]
23. Soluble CD89 is a critical factor for mesangial proliferation in childhood IgA nephropathy.
Cambier A; Gleeson PJ; Abbad L; Canesi F; da Silva J; Bex-Coudrat J; Deschênes G; Boyer O; Rabant M; Ulinski T; Hogan J; Peuchmaur M; Berthelot L; Monteiro RC
Kidney Int; 2022 Feb; 101(2):274-287. PubMed ID: 34756952
[TBL] [Abstract][Full Text] [Related]
24. Aberrantly glycosylated IgA1 as a factor in the pathogenesis of IgA nephropathy.
Tanaka M; Seki G; Someya T; Nagata M; Fujita T
Clin Dev Immunol; 2011; 2011():470803. PubMed ID: 21318178
[TBL] [Abstract][Full Text] [Related]
25. The Gut and Kidney Crosstalk in Immunoglobulin A Nephropathy.
Sanchez-Russo L; Rajasekaran A; Bin S; Faith J; Cravedi P
Kidney360; 2022 Sep; 3(9):1630-1639. PubMed ID: 36245664
[TBL] [Abstract][Full Text] [Related]
26. Glomerular Galactose-Deficient IgA1(KM55) Positive May Predict Poorer Prognosis in Coexisting Primary Membranous Nephropathy and IgA Nephropathy Patients.
Cheng W; Wang G; Guo W; Sun L; Xu X; Dong H; Ye S; Geng Y; Cheng H
Cells; 2022 Dec; 12(1):. PubMed ID: 36611910
[TBL] [Abstract][Full Text] [Related]
27. Paradigm shift in activity assessment of IgA nephropathy - optimizing the next generation of diagnostic and therapeutic maneuvers via glycan targeting.
Suzuki Y; Suzuki H; Yasutake J; Tomino Y
Expert Opin Biol Ther; 2015 Apr; 15(4):583-93. PubMed ID: 25604055
[TBL] [Abstract][Full Text] [Related]
28. Current understanding of IgA antibodies in the pathogenesis of IgA nephropathy.
Nihei Y; Suzuki H; Suzuki Y
Front Immunol; 2023; 14():1165394. PubMed ID: 37114051
[TBL] [Abstract][Full Text] [Related]
29. New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuria.
Smerud HK; Bárány P; Lindström K; Fernström A; Sandell A; Påhlsson P; Fellström B
Nephrol Dial Transplant; 2011 Oct; 26(10):3237-42. PubMed ID: 21378156
[TBL] [Abstract][Full Text] [Related]
30. Specific immune biomarker monitoring in two children with severe IgA nephropathy and successful therapy with immunoadsorption in a rapidly progressive case.
Cambier A; Dossier C; Hogan J; Baudouin V; Maisin A; Couderc A; Kwon T; Gleeson PJ; Monteiro RC
Pediatr Nephrol; 2022 Jul; 37(7):1597-1603. PubMed ID: 34997322
[TBL] [Abstract][Full Text] [Related]
31. Plasma galactose-deficient immunoglobulin A1 and loss of kidney function in patients with immunoglobulin A vasculitis nephritis.
Zhang X; Xie X; Shi S; Liu L; Lv J; Zhang H
Nephrol Dial Transplant; 2020 Dec; 35(12):2117-2123. PubMed ID: 31377786
[TBL] [Abstract][Full Text] [Related]
32. Galactose-Deficient IgA1 as a Candidate Urinary Polypeptide Marker of IgA Nephropathy?
Suzuki H; Allegri L; Suzuki Y; Hall S; Moldoveanu Z; Wyatt RJ; Novak J; Julian BA
Dis Markers; 2016; 2016():7806438. PubMed ID: 27647947
[TBL] [Abstract][Full Text] [Related]
33. [IgA nephropathy].
Floege J
Inn Med (Heidelb); 2023 Oct; 64(10):961-969. PubMed ID: 37672089
[TBL] [Abstract][Full Text] [Related]
34. [Considerations on the treatment of IgA nephropathy on the basis of the results of the latest studies (STOP-IgAN, TESTING, NEFIGAN)].
Nagy J; Sági B; Máté J; Vas T; Kovács T
Orv Hetil; 2017 Dec; 158(49):1946-1952. PubMed ID: 29199436
[TBL] [Abstract][Full Text] [Related]
35. Measurement of galactosyl-deficient IgA1 by the monoclonal antibody KM55 contributes to predicting patients with IgA nephropathy with high risk of long-term progression.
Martín-Penagos L; Fernández-Fresnedo G; Benito-Hernández A; Mazón J; de Cos M; Oviedo MV; San Segundo D; López-Hoyos M; Gómez-Román J; Ruiz JC; Rodrigo E
Nefrologia (Engl Ed); 2021; 41(3):311-320. PubMed ID: 36166247
[TBL] [Abstract][Full Text] [Related]
36. Glomerular deposition of galactose-deficient IgA1-containing immune complexes via glomerular endothelial cell injuries.
Makita Y; Suzuki H; Nakano D; Yanagawa H; Kano T; Novak J; Nishiyama A; Suzuki Y
Nephrol Dial Transplant; 2022 Aug; 37(9):1629-1636. PubMed ID: 35746884
[TBL] [Abstract][Full Text] [Related]
37. Post-transplant immunoglobulin A deposition and nephropathy in allografts.
Sofue T; Suzuki H; Ueda N; Kushida Y; Minamino T
Nephrology (Carlton); 2018 Jul; 23 Suppl 2():4-9. PubMed ID: 29968406
[TBL] [Abstract][Full Text] [Related]
38. IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-oriented pathogenesis.
Suzuki H; Yasutake J; Makita Y; Tanbo Y; Yamasaki K; Sofue T; Kano T; Suzuki Y
Kidney Int; 2018 Mar; 93(3):700-705. PubMed ID: 29329643
[TBL] [Abstract][Full Text] [Related]
39. Case report on mesangial proliferative glomerulonephritis with multicentric Castleman's disease: Approach to the onset mechanism of immunoglobulin A nephropathy.
Karasawa K; Ogura S; Miyabe Y; Akiyama K; Nitta K; Moriyama T
Clin Immunol; 2020 Mar; 212():108347. PubMed ID: 31978558
[TBL] [Abstract][Full Text] [Related]
40. Glucocorticoids Reduce Aberrant O-Glycosylation of IgA1 in IgA Nephropathy Patients.
Kosztyu P; Hill M; Jemelkova J; Czernekova L; Kafkova LR; Hruby M; Matousovic K; Vondrak K; Zadrazil J; Sterzl I; Mestecky J; Raska M
Kidney Blood Press Res; 2018; 43(2):350-359. PubMed ID: 29529610
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
